Your browser doesn't support javascript.
loading
HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.
Vaccari, Monica; Fourati, Slim; Gordon, Shari N; Brown, Dallas R; Bissa, Massimilano; Schifanella, Luca; Silva de Castro, Isabela; Doster, Melvin N; Galli, Veronica; Omsland, Maria; Fujikawa, Dai; Gorini, Giacomo; Liyanage, Namal P M; Trinh, Hung V; McKinnon, Katherine M; Foulds, Kathryn E; Keele, Brandon F; Roederer, Mario; Koup, Richard A; Shen, Xiaoying; Tomaras, Georgia D; Wong, Marcus P; Munoz, Karissa J; Gach, Johannes S; Forthal, Donald N; Montefiori, David C; Venzon, David J; Felber, Barbara K; Rosati, Margherita; Pavlakis, George N; Rao, Mangala; Sekaly, Rafick-Pierre; Franchini, Genoveffa.
  • Vaccari M; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Fourati S; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
  • Gordon SN; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Brown DR; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Bissa M; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Schifanella L; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Silva de Castro I; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Doster MN; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Galli V; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Omsland M; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Fujikawa D; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Gorini G; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Liyanage NPM; Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Trinh HV; US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • McKinnon KM; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Foulds KE; Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Keele BF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Roederer M; AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory, Frederick, MD, USA.
  • Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Shen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Wong MP; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Munoz KJ; Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
  • Gach JS; Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
  • Forthal DN; Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
  • Montefiori DC; Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
  • Venzon DJ; Division of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.
  • Felber BK; Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Rosati M; Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
  • Pavlakis GN; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
  • Rao M; Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
  • Sekaly RP; US Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • Franchini G; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Nat Med ; 24(6): 847-856, 2018 06.
Article en En | MEDLINE | ID: mdl-29785023
Qualitative differences in the innate and adaptive responses elicited by different HIV vaccine candidates have not been thoroughly investigated. We tested the ability of the Aventis Pasteur live recombinant canarypox vector (ALVAC)-SIV, DNA-SIV and Ad26-SIV vaccine prime modalities together with two ALVAC-SIV + gp120 protein boosts to reduce the risk of SIVmac251 acquisition in rhesus macaques. We found that the DNA and ALVAC prime regimens were effective, but the Ad26 prime was not. The activation of hypoxia and the inflammasome in CD14+CD16- monocytes, gut-homing CCR5-negative CD4+ T helper 2 (TH2) cells and antibodies to variable region 2 correlated with a decreased risk of SIVmac251 acquisition. By contrast, signal transducer and activator of transcription 3 activation in CD16+ monocytes was associated with an increased risk of virus acquisition. The Ad26 prime regimen induced the accumulation of CX3CR1+CD163+ macrophages in lymph nodes and of long-lasting CD4+ TH17 cells in the gut and lungs. Our data indicate that the selective engagement of monocyte subsets following a vaccine prime influences long-term immunity, uncovering an unexpected association of CD14+ innate monocytes with a reduced risk of SIVmac251 acquisition.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monocitos / Virus de la Inmunodeficiencia de los Simios / Vacunas contra el SIDA / Receptores de Lipopolisacáridos / Inflamasomas / Hipoxia Tipo de estudio: Etiology_studies / Qualitative_research / Risk_factors_studies Límite: Animals Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Monocitos / Virus de la Inmunodeficiencia de los Simios / Vacunas contra el SIDA / Receptores de Lipopolisacáridos / Inflamasomas / Hipoxia Tipo de estudio: Etiology_studies / Qualitative_research / Risk_factors_studies Límite: Animals Idioma: En Año: 2018 Tipo del documento: Article